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Ebolavirus NP oligomerizes into helical filaments
found at the core of the virion, encapsidates the viral
RNA genome, and serves as a scaffold for additional
viral proteins within the viral nucleocapsid. We
identified a portion of the phosphoprotein homolog
VP35 that binds with high affinity to nascent NP
and regulates NP assembly and viral genome bind-
ing. Removal of the VP35 peptide leads to NP self-
assembly via its N-terminal oligomerization arm.
NP oligomerization likely causes a conformational
change between the NP N- and C-terminal domains,
facilitating RNA binding. These functional data are
complemented by crystal structures of the NP-
VP35 complex at 2.4 A˚ resolution. The interactions
between NP and VP35 illuminated by these struc-
tures are conserved among filoviruses and provide
key targets for therapeutic intervention.INTRODUCTION
Ebola virus causes severe hemorrhagic fever and is responsible
for a significant and sustained outbreak in Western Africa 2013–
2015 (Agua-Agum et al., 2015; Burke et al., 1978). Ebola virus
belongs to the family Filioviridae, which also contains four other
members of the ebolavirus genus, as well as the pathogenic
Marburg virus (MARV), and the recently discovered Lloviu virus
(LLOV) (Negredo et al., 2011). Filoviruses belong to the order
Mononegavirales, which also contains the pathogenic respira-
tory syncytial virus (RSV), measles, mumps, Nipah, rabies, and
other viruses. All members of Mononegavirales bear a nonseg-
mented, negative-sense RNA genome (NNS) that is encapsi-
dated by a viral nucleoprotein, termed N or NP (Knipe and
Howley, 2001). The viral polymerase (L) and a phosphoprotein
polymerase cofactor (typically called P) direct viral transcription
and replication. In filoviruses, the phosphoprotein homolog is
VP35 (Mu¨hlberger et al., 1998), though this protein is not strongly
phosphorylated (Elliott et al., 1985). Filoviruses contain an addi-
tional polymerase co-factor, VP30, which facilitates read through
of RNA secondary structure in the ebolavirus NP transcript (Weik140 Cell Reports 12, 140–149, July 7, 2015 ª2015 The Authorset al., 2002), and contributes to the continuation of transcription
at gene junctions (Martı´nez et al., 2008). Filovirus NP binds both
VP35 and VP30 (Hartlieb et al., 2007; Huang et al., 2002), which
in turn both interact with the viral polymerase to assemble the
viral replication complex (Groseth et al., 2009; Trunschke et al.,
2013).
The nucleoproteins of NNS viruses also protect viral RNA ge-
nomes from recognition by the cellular innate immune response
and render the genome resistant to ribonucleases (Hornung
et al., 2006; Knipe and Howley, 2001). Recombinant expression
of ebolavirus NP in the absence of viral infection produces long
filament-like, helical NP coils bound to cellular RNA, suggesting
that the NP does not specifically recognize viral RNA (Bharat
et al., 2012; Mavrakis et al., 2002). The long helical NP filament
serves as a scaffold for the assembly of the filovirus nucleo-
capsid, which includes VP35, VP30, VP24, and L (Elliott et al.,
1985; Huang et al., 2002). NP oligomers further interact with
the matrix protein, VP40, allowing recruitment of the nucleo-
capsid into progeny virions (Noda et al., 2006). Themultiple func-
tions of Ebola virus NPmake NP an essential piece of machinery
for viral RNA synthesis and virus assembly alike.
Despite the importance of the NP protein to the ebolavirus life
cycle, the structure of its RNA-binding and self-assembling do-
mains, as well as the mechanisms for its oligomerization and
RNA binding, has remained elusive. However, nucleoprotein
structures for several other NNS viruses have been determined
(Alayyoubi et al., 2015; Albertini et al., 2006; Green et al., 2006;
Rudolph et al., 2003; Tawar et al., 2009; Yabukarski et al.,
2014). These structures reveal a shared general fold in which
N- and C-terminal domains form a bi-lobed structure with RNA
binding in a cleft between the two lobes. In the oligomeric
nucleoprotein structures available, N- and C-terminal arms or
loops extend from each of these lobes to contact adjacent nucle-
oproteins in the oligomer. In many NNS viruses, the viral phos-
phoprotein (P) contains a peptide in its N-terminal region, which
chaperones the viral nucleoprotein (N) in a monomeric, RNA-free
state called N-P (Curran et al., 1995; Leyrat et al., 2011; Majum-
dar et al., 2004; Yabukarski et al., 2014). This P peptide prevents
premature nucleoprotein oligomerization and aberrant, non-pro-
ductive interactions of nascent nucleoprotein with cellular RNA.
Two crystal structures of N-P have so far been described.
For vesicular stomatitis virus (VSV), P directly blocks both
the nucleoprotein RNA-binding site and the binding site of the
Figure 1. Pulldown of NP with VP35 Trunca-
tions
HA-tagged EBOV VP35 constructs were co-ex-
pressed with NP and pulled down on anti-HA
beads.
(A) The Western blotting results probing for VP35
(anti-HA) or NP. The ‘‘NP lysate’’ positive control is
cleared cell lysate from cells transfected with NP
alone. The ‘‘VP35’’ negative control is an anti-HA
pulldown of cells transfected with NP alone.
(B) Results summary of the pulldown experiment.nucleoprotein N-terminal arm domain, preventing RNA binding
and nucleoprotein oligomerization (Leyrat et al., 2011). In the
Nipah virus N-P structure, the P peptide does not occlude the
RNA-binding site and instead likely interferes with the binding
of both the N- and C-terminal arms of adjacent nucleoproteins
(Yabukarski et al., 2014). Additionally, the Nipah virus N struc-
ture is in an open conformation, while the oligomeric, RNA-
bound nucleoprotein of RSV is in a closed conformation (Tawar
et al., 2009). The open conformation of Nipah N-P is believed
to be incapable of binding to RNA. Despite the commonality of
N-P complexes among NNS viruses, filovirus VP35 were previ-
ously hypothesized to lack this chaperoning activity (Noda et al.,
2011).
In this work, we identify an N-terminal binding site on filovirus
VP35 for NP and demonstrate that this VP35-NP interaction
chaperones the NP in a monomeric, RNA-free state. We term
this complex NP-VP35. Characterization of this complex has al-
lowed us to determine crystal structures of the Ebola virus NP
core domain bound to a VP35 peptide to 2.4 A˚ resolution in mul-
tiple space groups. The interactions observed in these structures
are conserved across the filovirus family. Accompanying bio-
physical analyses demonstrate that the VP35 N-terminal peptide
binds NP with high affinity and that binding is coupled to confor-
mational changes in one or both proteins. We further identify the
N- and C-terminal oligomerization arms of the Ebola virus NP
and show their importance in the formation of large NP polymers.
Further data also demonstrate that the binding of RNA to NP is
dependent on NP oligomerization, rather than the absence of
the VP35 N-terminal peptide chaperone. Based on these results,
we propose a structure-based model for the assembly of the
oligomeric Ebola virus NP from newly synthesized NP.
RESULTS
Identification of a Second NP Binding Site on VP35
To examine the interactions between Ebola virus (EBOV, formerly
known as Zaire ebolavirus, ZEBOV) VP35 and NP, we prepared a
series of N- and C-terminal truncations of VP35, each containing
an HA-epitope tag for purification and detection. Each truncation
construct was designed to incorporate the HA tag such that one
native terminus is preserved in each construct (i.e., N-terminal
truncations contain N-terminal HA tags). We co-transfected
each of these VP35 constructs with NP into HEK293T cells.
Western blotting of anti-HA pulldowns for VP35 (anti-HA) and NP(Figure 1) clearly shows that either VP35 1–80 or VP35 80–340
are sufficient to pull down NP. Hence, VP35 has two unique and
independent binding sites for the viral NP: residues 1–80 and
80–340. The VP35 80–340 region contains a putative coiled-coil
oligomerization domain (residues 80–120) (Reid et al., 2005), as
well as a folded C-terminal domain (residues 219–340) (Kimberlin
et al., 2010; Leung et al., 2010). A previous study (Prins et al., 2010)
showed that theC-terminal domainof VP35binds toNP.Our iden-
tification of a stronger interaction by residues 80–340 than 219–
340 suggests a role for VP35 oligomerization in enhancing the
avidity of the VP35 C-terminal domain interaction. Comparison
of the N-terminal sequence (residues 1–80) of EBOV VP35 to
that of the other ebolaviruses, and more broadly to other filovi-
ruses, highlights a region of high sequence conservation (Fig-
ure 2A) (Karlin and Belshaw, 2012).
The VP35 Peptide Chaperones NP in a Monomeric Form
The N-terminal 450 residues of NP were previously shown to be
sufficient for RNA binding and oligomerization of NP (Bharat
et al., 2012; Watanabe et al., 2006). We hypothesized that the
VP35 N-terminal 1–80 peptide identified by the pulldown may
play a role in chaperoning the NP, analogous to the P proteins
of other nonsegmented negative-sense RNA viruses. To test
this hypothesis, we co-expressed the VP35 1–80 peptide and
NP amino acids 1–450 in E. coli. We observe that NP 1–450
co-purifies with His-tagged VP35 1–80. The co-purification of
these regions of VP35 and NP confirms the results of the pull
down and indicates that the VP35 N-terminal peptide interacts
with the N-terminal 450 amino acids of NP. Size-exclusion chro-
matography with in-line multiangle light scattering (SEC-MALS)
indicates this sample to be a monomer in solution (Table 1, sam-
ple 1). However, over time, this sample gradually shifts to larger
molecular weight species.
To stabilize the VP35 1–80-NP 1–450 complex, the two pro-
teins were engineered as a fusion. The VP35 1–80-NP 1–450
fusion protein was similarly monomeric in solution (Figure S1;
Table 1, sample 3) and purified completely free of E. coli nucleic
acids. In addition, the corresponding fusion proteins for Sudan
ebolavirus (SUDV) and MARV and the full-length EBOV NP are
also monomeric (Table 1, samples 4–6) and RNA-free, as deter-
mined by the ratio of their UV absorbance at 260 and 280 nm. To
characterize the EBOV VP35 1–80-NP 1–450 fusion protein, we
performed hydrogen/deuterium exchange mass spectrometry
(H/DXMS). This analysis illustrates that VP35 residues 18–47Cell Reports 12, 140–149, July 7, 2015 ª2015 The Authors 141
Figure 2. Structure of the NP-VP35 Complex
(A) Sequence alignment of the conserved VP35 N-terminal peptide. Amino
acids sharing identity with EBOV are shaded pink, and similar amino acids are
shaded orange. Amino acids participating in helices as observed in the crystal
structure are indicated at top by boxes. Amino acid positions within 4 A˚ of NP
are indicated with black dots above the alignment.
(B) Stereoview of the NP-VP35 crystal structure. NP is colored from the
N terminus (blue) to the C terminus (red) with the VP35 peptide in magenta.
(C) The VP35 peptide (orange) uses a hydrophobic face and conserved amino
acids to contact the NP (green).
See also Figures S2 and S3 and Table S1.
Table 1. EBOV NP Oligomerization Assessed by Multiangle Light
Scattering
No. Sample
VP35 1–80
Added
Monomeric
NP (kDa)
Calculated
NP
MALS
Monomeric NP-VP35 Co-expression
1 EBOV VP35 1–80 + NP 1–450 50 72
2 EBOV NP 1–450, AEX 50 >1,000
Monomeric NP-VP35 Fusions
3 EBOV VP35 1–80-NP 1–450 61 58
4 EBOV VP35 1–80-NP 1–739 94 110
5 SUDV VP35 1–49-NP 1–450 58 52
6 MARV VP35 1–41-NP 1–430 54 51
7 EBOV VP35 15–60-NP 34–367 42 40
RNA-Independent NP Oligomerization and Reversibility
8 EBOV VP35 1–80-TEV-NP
1–450
60 74
9 EBOV VP35 1–80 + NP 1-450,
TEV cleaved
50 70
10 EBOV NP 1–450,
TEV cleaved, AEX
50 >1,000
11 EBOV NP 1–450 + 50 74
Importance of Terminal Arm Domains in NP Oligomerization
12 EBOV NP 34–367 40 38
13 EBOV NP 34–367 + 40 51
14 MBP-EBOV NP 34–367 81 78
15 MBP-EBOV NP 34–367 + 81 85
16 MBP-EBOV NP 34–450 90 88
17 MBP-EBOV NP 1–367 85 >1,000
18 MBP-EBOV NP 19–389 85 >1,000
Oligomeric NP-RNA
19 MBP-EBOV NP 1–450 94 >1,000
20 MBP-EBOV NP 1–450 + 94 >1,000
21 EBOV NP 1–450 50 >1,000
22 EBOV NP 1–450 + 50 >1,000
23 MBP-EBOV NP 1–739 127 >1,000
24 MBP-EBOV NP 1–739 + 127 >1,000
Calculatedmolecular weights are based on the expectedmass of a single
NP. Multiangle light-scattering data were collected with SEC-MALS. In
the sample column, hyphens between two protein domains represent
protein fusions, whereas plus signs indicate two distinct protein chains
whether the result of co-expression or the result of a TEV protease cleav-
age. The data representing the co-expression of NP with VP35 (samples
1–2) or the RNA-independent NP oligomerization and reversibility of this
oligomerization (samples 8–11) represent a single protein preparation
that was subsequently processed with additional steps such as cleavage
by TEV protease, purification by anion exchange chromatography (AEX),
or addition of purified VP35 1–80 peptide. See also Figure S1 for imaging
of selected samples with negative stain electron microscopy.are protected from solvent exchange in the presence of NP
1–450 (Figure S2). These solvent-protected VP35 residues
correspond closely to those conserved across ebolaviruses.
H/DXMS also shows that NP residues 39–356 exchange more
slowly with solvent than the terminal regions and suggests that
NP 39–356 forms a folded core.
We hypothesized that the folded core of EBOV NP corre-
sponds to the bi-lobed fold of other NNS virus nucleoproteins
(Tawar et al., 2009). We further hypothesized the presence of
additional N- andC-terminal arms of the EBOVNP,which appear
free to solvent exchange in the chaperoned monomeric fusion
protein and would ordinarily facilitate NP oligomerization in the
absence of VP35. Using SEC-MALS and isothermal titration
calorimetry (ITC), we found that a protein construct containing
the folded NP core, but excluding the terminal regions (NP
34–367) is monomeric and capable of binding the VP35 1–80
peptide (Figure 3; Table 1, samples 12 and 13). Correspondence
between these solution binding data for the NP-VP35 interac-
tion and the solvent protection observed by H/DXMS for the
VP35 1–80-NP 1–450 fusion protein demonstrates the VP35-
NP fusion protein is an accurate model of NP-VP35. These
data support the conclusion that the EBOV VP35 N-terminal
peptide chaperones NP as a monomeric, RNA-free NP-VP35
complex.
VP35 Chaperoning of NP Mechanism: Structure and
High-Affinity Binding
In order to use crystallography to understand the mechanisms of
interaction in the NP-VP35 complex, we constructed a fusion142 Cell Reports 12, 140–149, July 7, 2015 ª2015 The Authorsprotein lacking extraneous regions of VP35 and NP that freely
exchange with solvent (Table 1, sample 7). This fusion protein
(VP35 15–60-NP 34–367) crystallizes and diffracts to 2.4 A˚. The
structure could not be solved by molecular replacement using
the known NNS virus nucleoproteins or nucleoprotein domain
Figure 3. VP35 N-Terminal Peptide and NP Core Interactions
(A) ITC was used to assess the binding of the VP35 1–80 peptide to the folded
NP core (NP 34–367). A representative trace is presented for the binding
reaction using WT VP35 1–80.
(B) Activity of VP35 mutants in the mini-genome assay presented as a per-
centage of WT VP35 activity.
(C) VP35 21–46 peptide from the NP-VP35 complex. Mutated positions are
labeled. Carbon atoms within 4 A˚ of NP are colored green. Leucine 33 is
buried by other VP35 residues. It does not directly contact NP.
(D) Calculated molecular dissociation constants for the WT interaction and
various VP35 1–80 mutants with corresponding activities in the mini-genome
assay. The reported error represents the SD of three replicate experiments. For
the M35P and L33D mutants, there was no observed binding in the ITC
experiment using 30-mM NP core and 300-mM mutant VP35 1–80.
See also Figure S5.
Figure 4. Comparison of the Ebola Virus NP-VP35 Complexwith the
RSV N-RNA Complex
(A) Chain A of PDB 2WJ8 was superimposed onto the Ebola virus NP core
domain-VP35 N-terminal peptide complex using the nucleoprotein C-terminal
domains. A transition from the open state (monomeric EBOV NP) to the closed
state (oligomeric RSV N) is likely necessary to form the RNA-binding site,
which is not occluded by the EBOV VP35 peptide
(B) The EBOV VP35 N-terminal peptide occupies the site on EBOV NP core
that is bound by the N-terminal oligomerization arm of an adjacent nucleo-
protein (NPi1) in the oligomeric RSV N structure. For a structural alignment of
the individual N- and C-terminal domains of RSV and EBOV NP.
See also Figure S4.structures as search models. Instead, we determined the struc-
ture of the complex using x-ray crystallography with sulfur-SAD
phasing from endogenous protein sulfur atoms. The experimen-
tally phased structure was then used as a search model for
molecular replacement to solve the structure of VP35 15–60-
NP 34–367 in two additional space groups (Table S1).
The structure of the EBOVNPRNA-binding domain is primarily
a-helical and is composed of N- and C-terminal domains that
together form a bi-lobed structure (Figure 2B). Nearly all residues
were resolved, with the exception of a handful of disordered
amino acids at the N and C termini of NP and VP35, as well as
sparse electron density in a region spanning residues 121–143
of NP. This region of NP has high B factors for the residues
modeled in each space group and corresponds to a region of
high solvent exchange in H/DXMS (Figure S2), reflecting the
inherent flexibility of these amino acids. These residues are
best ordered in the P22121 space group (4ZTG).
The VP35 N-terminal peptide binds to one side of the C-termi-
nal domain of the NP core (Figure 2C) and adopts an unusual
straddling conformation as compared to other NNS virus P
homologs. The P peptides observed to chaperone VSV or Nipahvirus nucleoproteins are primarily a-helical (Leyrat et al., 2011;
Yabukarski et al., 2014). However, the 26 amino acids of the
EBOV VP35 peptide ordered in the structure are mostly lacking
secondary structure and contain only 12 amino acids in a helical
conformation. The N terminus of the VP35 peptide lies near the C
terminus of the NP core, and the VP35 chain progresses toward
the junction of the NP N- and C-terminal domains. However,
before reaching this junction, the VP35 peptide chain abruptly
turns and progresses toward the rear of the C-terminal domain.
The path of the VP35N-terminal peptide allows the VP35 peptide
to straddle a b-hairpin in the NP C-terminal domain. This
b-hairpin is unique to Ebola virus NP and is not observed in
known nucleoprotein structures of other NNS viruses.
The chaperoning VP35 peptide buries 1,260 A˚2 of molecular
surface on NP. The interacting region of VP35 contains both
hydrophilic and hydrophobic regions. However, the buried sur-
face of NP is primarily hydrophobic and involves both the body
of the C-terminal domain as well as the ebolavirus-specific, NP
b-hairpin. Many of the interacting residues on VP35 and NP are
highly conserved across the ebolavirus genus and to a lesser
extent across the filoviruses family (Figures 2A and S3).
The bi-lobed fold of the EBOV NP is most similar to that of the
closely related RSV (Tawar et al., 2009), parainfluenza virus 5
(PIV5) (Alayyoubi et al., 2015), and Nipah virus (Yabukarski et al.,
2014) nucleoproteins. The C-terminal domains of the EBOV and
RSV nucleoproteins structurally align more closely, while the
N-terminal domains are more divergent (Figure S4). Structural
alignment of the oligomeric RSV N and the monomeric EBOV
NP core-VP35 peptide complex shows the EBOV NP core
to be in an open conformation (Figure 4) similar to Nipah
virus N-P. Homology with the RNA-bound RSV nucleoprotein
suggests the RNA-binding site of EBOV NP runs between theCell Reports 12, 140–149, July 7, 2015 ª2015 The Authors 143
N- and C-terminal domains. The RNA-binding site of RSV nucleo-
protein is composed of regions from both the N- and C-terminal
domains. In contrast to RSV nucleoprotein, the EBOV NP-VP35
structure is in anopenconformationwith the twodomains splayed
apart. Hence, this monomeric complex is unlikely to bind RNA.
To examine the binding of VP35 to NP, we performed ITC using
the VP35N-terminal peptide (1–80) and the NP core domain (34–
367). The interaction between these two partners is remarkably
strong, with an equilibrium KD of 1.1 ± 0.2 nM (Figure 3). We
mutated the VP35 N-terminal peptide N-terminal to and within
the first helical region. Mutated VP35 1–80 was used in ITC anal-
ysis, while full-length VP35 mutants were used in Ebola virus
mini-genome assays. While the ITC assays directly measure the
strength of the interaction between the NP core and VP35 N-ter-
minal peptide, the mini-genome assay assesses the abilities of
these mutants in the background of full-length viral proteins in
mammalian cells to support replication/transcription of a reporter
gene whose expression is controlled by viral sequences (Ja-
senosky et al., 2010). Selected VP35 hydrophobic amino acids
were mutated to aspartate to disrupt hydrophobic interactions.
Additional amino acid positionsweremutated to proline to disrupt
the peptide backbone conformation. All of the VP35 mutants
negatively affected protein binding in ITC although to greatly
differing extents (Figure 3). Aspartate mutations to hydrophobic
residues with solvent-exposed side chains or a proline mutation
within a non-helical region had minimal effects on VP35 binding;
these mutants maintain high-affinity binding with KDs of less
than 20 nM. These same mutations maintain at least WT activity
to support mini-genome replication/transcription with two of the
mutants showing enhancements in reporter expression over the
WT VP35. While these positions are highly conserved in ebolavi-
ruses, they are polymorphic across the filoviruses, reflecting their
lesser importance in maintaining the NP-VP35 interaction. In
contrast, aspartate mutations to VP35 hydrophobic residues
buried in the NP-VP35 complex or proline mutations targeted
to helical regions had low affinities for NP, having KDs of 1 mM
or greater. The mutations with detrimental effects on VP35 bind-
ing to NP in ITC further have minimal activity in the replication/
transcription of the EBOV mini-genome. VP35 positions, which
have detrimental effects in either the ITC binding assay or the
mini-genome assay, are much more highly conserved across
the filovirues family. This indicates the importance of the first he-
lical region and buried hydrophobic amino acids in maintaining
the interaction. The experimentally measured effects of each of
these mutations accurately correspond to predictions made
from the NP core-VP35 peptide complex crystal structure and
the VP35 sequence alignment across the filovirus family.
Because the crystal structures reveal such a large hydrophobic
binding surface between VP35 and NP, we characterized the
burial of non-polar surface area upon binding in solution using
ITC. By measuring the change in enthalpy (DH) upon VP35 1–80
binding to the NP core domain at different temperatures, we
calculated a heat capacity change upon binding (DCp) of 946
cal mol1 K1 (Figure S5). This DCp indicates that approximately
3,400 A˚2 of nonpolar surface is buried upon VP35 peptide binding
to the NP core (Ha et al., 1989). However, this large buried non-
polar surface area is far greater than the 2,520 A˚2 of total area
buriedasobserved in ourNP core-VP35N-terminal peptide crys-144 Cell Reports 12, 140–149, July 7, 2015 ª2015 The Authorstal structure (Krissinel and Henrick, 2007) and is strongly sugges-
tive of a significant conformational change upon binding in either
orbothVP35andNPproteins toburyadditional non-polar surface.
Using trends in theentropychangeuponbinding (DS)with temper-
ature and theDCp, we estimate that uponVP35 peptide binding to
NP core, approximately 43 amino acids are rigidified (Spolar and
Record, 1994). As ITCmeasures the observed change in the ther-
modynamic parameters between the starting components and
final complex, it is difficult to assign these changes to either NP
core or VP35 peptide. The loss of flexibility in the VP35 N-terminal
peptide bybinding theNP core is likely to contribute substantially
to the rigidification. However, we observe only 26 amino acids of
VP35consistently in thecrystal structuresandonly30aminoacids
of VP35 are protected from solvent exchange in H/DXMS. The
difference between these figures and the 43 amino acids in
total that are rigidified demonstrate additional rigidification occurs
beyond that accounted for by the VP35 peptide. Therefore, even if
the VP35 N-terminal peptide rigidifies from a completely flexible
peptide to the bound form observed in the crystal structure, these
data predict a decrease in the number of conformational states
within NP core upon VP35 peptide binding.
Removal of the Peptide Causes NP Oligomerization
In Vitro
While NP 1–450 co-expressed with VP35 1–80 initially purifies as
a monomer (Table 1, sample 1), prolonged storage leads to the
gradual formation of large oligomers. We exploited this phenom-
enon to explore the oligomerization dynamics of NP starting
with NP-VP35 monomers. When the VP35 1–80 peptide is
purified away from NP 1–450 using anion exchange chromatog-
raphy, the NP forms oligomers (Table 1, sample 2). The chro-
matographic separation of the NP-VP35 complex into its con-
stituents is only possible when using NP constructs containing
regions sufficient for NP oligomerization (for example, NP
1–450 and not for the shorter NP core, 34–367). To obtain better
control of oligomerization and to produce preparations of NP
free from any contaminating cellular RNA, we constructed a
TEV protease-cleavable VP35 1–80-NP 1–450 fusion protein.
This construct expresses as an RNA-free monomer (Table 1,
sample 8). After TEV cleavage, the VP35-bound NP 1–450 re-
mains mostly monomeric (Table 1, sample 9) with some of the
NP losing its VP35 1–80 and shifting to higher oligomers. The
monomeric nature of the fusion protein cleaved with TEV prote-
ase mirrors that of the co-expressed VP35 1–80 and NP 1–450
supporting the use of this system to examine NP oligomerization.
Anion exchange chromatography completely removes the
TEV protease-cleaved VP35 peptide from NP 1–450, shifting
the entire NP sample to large oligomers (Table 1, sample 10).
To eliminate the possibility that the observed large oligomers
may be soluble aggregates, we imaged this sample using nega-
tive-stain electron microscopy. The RNA-free, VP35-free, oligo-
meric NP forms large ring-like structures approximately 50 nm in
diameter (Figure S1). This is analogous to the ring formation of
VSV, Rabies virus and RSV nucleoproteins using heterologous
expression systems (Albertini et al., 2006; Green et al., 2006; Ta-
war et al., 2009), although the rings formed by EBOV NP are
considerably larger. The assembly of NP into large oligomers in-
dicates that removal of the VP35 N-terminal peptide allows the
EBOV NP to oligomerize in vitro and that NP oligomerization is
independent of RNA binding. Furthermore, the oligomerization
of the RNA-free EBOV NP 1–450 is reversible. Incubating oligo-
meric NP 1–450 with an excess of VP35 1–80 peptide overnight
reverts the sample entirely to amonomeric form (Table 1, sample
11). Our data demonstrate that competition exists between the
binding of the VP35 N-terminal peptide and NP oligomerization.
We aligned the crystal structures of the monomeric EBOV NP
core-VP35 peptide complex with the oligomeric RSV nucleopro-
tein (2WJ8.pdb). This alignment shows an overlap between the
binding sites of the EBOV VP35 21–46 peptide and the RSV
nucleoprotein N-terminal arm from an adjacent protomer on
the nucleoproteins’ core domains (Figure 4B). The adjacent
RSV protomer is in the 30 direction along the bound RNA strand
(Ni1). The structural and functional homology between EBOV
and RSV nucleoproteins leads us to hypothesize that EBOV
VP35 directly competes with the N-terminal arm of other NP pro-
tomers to prevent NP oligomerization andmaintain NP as mono-
meric NP.
NP Oligomerization Domains
We performed H/DXMS analysis of the oligomeric, RNA-free
EBOV NP 1–450 to examine NP oligomerization (Figure S2).
Comparison of the oligomeric NP with the monomeric NP-
VP35 indicates that a shared folded core (NP 39–356) is main-
tained in both samples, though the C-terminal region of the NP
core is better protected from solvent exchange in the oligomeric
sample than the monomeric sample. Additionally, NP regions
20–29 and 357–381 show protection from solvent exchange
uniquely in the oligomeric NP sample, suggesting that these
are the N- and C-terminal oligomerization arms of NP. To test
this hypothesis, we produced a series of constructs lacking
one or both terminal regions, as well as a protein construct trun-
cated to contain the putative minimal oligomerization arms.
These protein constructs were expressed as MBP-fusion pro-
teins to facilitate their purification by affinity chromatography,
and the NP oligomeric state was assessed by SEC-MALS. The
fusion of MBP was found to not impair NP oligomerization (Fig-
ure S1; Table 1, samples 19 and 21). Deletion of the C-terminal
arm domain had no effect on protein oligomerization (Table 1,
sample 17). However, deletion of the N-terminal arm domain
rendered the protein monomeric (Table 1, sample 16). Deletion
of both arm domains also yields monomeric protein, as also
observed with non-MBP tagged NP core (Table 1, samples 12–
15). Finally, the NP core containing both of the putative minimal
N- and C-terminal arms (NP 19–389) was oligomeric (Table 1,
sample 18) in agreement with the oligomeric NPH/DXMS results.
NP 19–389with theminimal oligomerization arms was confirmed
to form oligomeric NP rings by electron microscopy (Figure S1).
Our crystal structure of the EBOV NP core-VP35 N-terminal
peptide complex and structural homology with the RSV nucle-
oprotein (Tawar et al., 2009) suggests that the EBOV VP35
N-terminal peptide directly competes for NP binding with the
N-terminal oligomerization arm of the NPi1. However, VP35
is not expected to interfere with the binding of the C-terminal
oligomerization arm of the NPi+1 protomer. Our SEC-MALS an-
alyses demonstrate that only the N-terminal arm domain is
required for NP oligomerization and that the C-terminal armdomain is non-essential. These oligomerization and the struc-
tural data indicate that it is sufficient for VP35 to block the bind-
ing of the NP N-terminal arm in order to maintain the EBOV NP
in a monomeric state.
NP Oligomerization Allows RNA Binding
Wedetermined that all of themonomeric NP constructs could be
purified free of E. coli RNA regardless of whether the VP35 1–80
peptide was present to chaperone NP. However, oligomeric NP
1–450 co-purifies with RNA, which could not be dissociated.
These anecdotal data suggest that there is a connection between
RNA binding and the oligomeric state of the NP. As noted above,
theEBOVNP core-VP35peptide complex structure is in anopen
conformation similar toNipah virusN-P (Yabukarski et al., 2014).
As the NP RNA-binding site is likely a composite of amino acids
contributed by the N- and C-terminal domains, we predict that
the EBOV NP open conformation with these domains splayed
apart is incapable of presenting a fully formed RNA-binding site
as observed in the RSV nucleoprotein closed conformation (Ta-
war et al., 2009). The VP35 N-terminal peptide binds to the side
of the C-terminal NP core domain and does not occlude the
RNA binding site, in contrast to the VSV N-P complex (Leyrat
et al., 2011). The VP35 peptide also makes only limited contact
with the N-terminal domain and is not expected to clash with a
closed conformation of EBOV NP. Thus, VP35 is unlikely to
directly block such a conformational transition.
We hypothesized that rather than directly preventing the bind-
ing of NP to RNA or modulating the conformational transition
from open to closed states, the VP35 chaperone functions to
maintain NP in a monomeric form and that this monomeric
form does not have an appreciable affinity for RNA. We tested
this hypothesis by measuring the binding of RNA to monomeric
or oligomeric NPs using fluorescence anisotropy. The oligomeric
NP 1–450 readily binds to an 18 nucleotide RNA with low nano-
molar affinity (20 nM) (Figure 5). However, neither of the mono-
meric NPs—chaperoned NP core-VP35 peptide complex and
unchaperoned NP core (NP 34–367)—show any significant
binding to RNA with protein concentrations up to 20 mM. These
data suggest that even without the VP35 peptide, monomeric
NP remains in an open conformation incapable of binding RNA.
The VP35 Peptide Does Not Dissociate Large NP-RNA
Oligomers
Above, we determined that NP oligomerization was not depen-
dent on bound RNA and that RNA-free NP 1–450 oligomers
could be reverted to a monomeric NP by incubating the oligo-
mers with the VP35 N-terminal peptide. However, NP purified
directly from E. coli in an oligomeric form contains bound cellular
RNA as assessed by the ratio of UV absorbance at 260 and
280 nm. Incubation of either the RNA-bound NP 1–450 or
RNA-bound full-length NP with the VP35 N-terminal peptide
did not convert oligomeric NP to a monomeric form (Table 1,
samples 19–24). This suggests that while not required for oligo-
merization, RNA stabilizes the oligomeric NP complex. This
result indicates that the VP35 N-terminal peptide is not capable
of disassembling NP oligomer-RNA complexes into NP-VP35
during viral replication to expose the RNA genome for RNA syn-
thesis by the viral polymerase.Cell Reports 12, 140–149, July 7, 2015 ª2015 The Authors 145
Figure 6. Ebolavirus VP35-NP and Assembly of NP-RNA
This cartoon model of the assembly of NP-RNA oligomers from VP35-NP
monomers depicts the interactions between VP35 and NP as well as adjacent
NPs. The NP core is shown in light green with terminal arms in dark green. The
C-terminal tails are depicted as dashed lines. RNA is colored yellow, and VP35
is in orange. Termini of proteins are labeled with N or C. The incoming VP35-
NP complex must displace the VP35 bound to the NP-RNA in order to
continue the encapsidation of the viral RNA in the 50 to 30 direction. Once the
VP35 has been displaced, its former binding site on NP is occupied by the
N-terminal arm of the incoming NP-VP35 complex and the incoming NP un-
dergoes a transition from an open to a closed conformation to bind RNA.
Figure 5. Ebolavirus Nucleoprotein RNA Binding
The potential of different NP constructs to bind a FITC-labeled 18 nucleotide
RNA was assessed. Binding was measured by changes in the fluorescence
anisotropy of the FITC-RNA with increasing protein concentrations. The olig-
omeric NP 1–450 (squares) shows 50% binding at a protein concentration of
20 nM. No appreciable binding is observed for the monomeric NP-VP35
complex (circles, VP35 15–60-NP 34–367 protein fusion) or for the monomeric
NP core (triangles, NP 34–367). Error bars represent the SD of three replicate
experiments.DISCUSSION
Our work has demonstrated that the EBOV VP35 contains a
conserved peptide near its N terminus, which is used to
chaperone viral NP in a high-affinity NP-VP35 complex. Our
structures of the NP core-VP35 N-terminal peptide complex
demonstrate that the VP35 N-terminal peptide binds a hydropho-
bic site on the side of theNPC-terminal domain. Further, the VP35
peptide adopts a unique conformation to straddle a b-hairpin so
far only observed in filovirus NP. The EBOV VP35 N-terminal pep-
tide binds to the NP corewith very high affinity, and the binding is
coupled toconformational changes inbothNPandVP35.Wehave
also identified the EBOVNP oligomerization arms and shown that
NP oligomerization is dependent on the N-terminal arm, which
likely competes directly with the VP35 N-terminal peptide. The
RNA-binding affinity of NP is not directly modulated by the pres-
ence of the VP35 N-terminal peptide, but rather indirectly by pre-
venting NP oligomerization: neither the monomeric NP core nor
NP core-VP35 peptide complex bind to RNA with any appre-
ciable affinity. Finally, we have shown that the VP35 N-terminal
peptide can reverse the oligomerization of RNA-free NP oligo-
mers, but has no effect on RNA-bound NP oligomers. The struc-
tural and biochemical analysis performed here allows us to
present a workingmodel for ebolavirus NP assembly into a nucle-
ocapsid-like oligomer (Figure 6) and provides insights into NP’s
role as a part of the viral RNA synthesis machinery.
In our model for NP assembly into nucleocapsids, newly syn-
thesized NP is chaperoned by high-affinity binding to the N-ter-
minal region of VP35 creating a NP-VP35 chaperone complex.
The chaperoned NP must then find its way to an actively repli-
cating nucleocapsid. As VP35 contains two independent binding
sites for NP, the VP35 C-terminal domain may associate with
nascent nucleocapsids thus guiding NP to the RNA synthesis
machinery. Alternatively, this may also be accomplished by
VP35 binding to the viral polymerase, L.146 Cell Reports 12, 140–149, July 7, 2015 ª2015 The AuthorsThe extremely high-affinity binding of the VP35 N-terminal
peptide to NP would suggest that VP35 does not simply fall off
of the NP. Rather, this suggests that a process must occur in
order to displace the VP35 peptide from NP. As the VP35 pep-
tide is able to dissociate NP oligomers in the absence of RNA
in vitro, NP oligomerization alone is unlikely to be sufficient to
displace the VP35 peptide from NP. Because the NP core
domain, with or without bound VP35 N-terminal peptide, does
not have appreciable affinity for RNA, RNA binding alone is also
not likely to be the driving force behind VP35 peptide removal.
It is possible that the peptide is actively removed by a protein
component of the viral RNA replication machinery. Alternatively,
the coupled process of NP oligomerization and concurrent
RNA binding at the viral replication complex may provide the
necessary force to displace the VP35 N-terminal peptide.
Removal of the VP35 N-terminal peptide would reveal the hy-
drophobic surface on the C-terminal domain of NP. Once this
surface has been exposed, NP rapidly oligomerizes using its N-
and C-terminal arms, spanning amino acids 20–38 and 356–
381, respectively. Based on homology with RSV nucleoprotein,
it is likely that the N-terminal oligomerization arm of an incoming
NP occupies the hydrophobic surface formerly occupied by the
VP35N-terminal peptide tobecome theNPi1 protomer (Figure 6).
We predict that the oligomerization of NP will trigger a conforma-
tional change between the N- and C-terminal domains transition-
ing the protein froman open to a closed form capable of efficiently
binding RNA. It has been demonstrated for VSV that phosphopro-
tein induces nucleoprotein to bind specifically to viral RNAs (Chen
et al., 2013). As the RNA binding by EBOV NP is believed to be
non-specific but is nonetheless a high-affinity interaction (Fig-
ure 5), RNA binding by NP is likely to occur concurrently with or
in very rapid succession to the removal of the VP35 N-terminal
peptide and oligomerization of NP in order to ensure that only viral
RNA and not cellular RNA is encapsidated.
In the availableRNA-boundNNSvirus nucleoprotein structures,
the encapsidatedRNA is hypothesized to be inaccessible for RNA
synthesis andmust first be displaced from the nucleoprotein prior
to its use asa templateby the viral polymerase (Greenet al., 2006).
Given the ability of the EBOV VP35 N-terminal peptide to
dissociate EBOVNPoligomers, it is tempting to conclude that this
peptide plays a role in disassembling NP oligomers during RNA
synthesis to allow the viral polymerase to gain access to the
genome. However, our in vitro data show that oligomeric NP-
RNA complexes cannot be dissociated by the VP35 N-terminal
peptide. It is possible, though, that the VP35 N-terminal peptide
may play a role in chaperoning the viral NP after RNA has been
released during the transient disassociation of the RNA from the
nucleocapsid that is believed to take place during NNS viral RNA
synthesis (Green et al., 2006). It is also possible that the VP35
N-terminal peptide binds to the viral NP at the RNA genome 30
end as this NP would not have an adjacent NPi1 protomer N-ter-
minal arm occupying the VP35 peptide-binding site (Leyrat et al.,
2011). A bound VP35 at the 30 end of the viral nucleocapsid could
serve to recruit the viral polymerase, L, to the RNA genome tran-
scription start site for viral transcription and replication.
During the preparation of this work, a second group working
independently determined a crystal structure of an EBOVNP frag-
ment bound to a VP35 peptide to 3.7 A˚ resolution (Leung et al.,
2015). This structure and most of the accompanying data are
consistent with the findings presented here. However, we do
note several differences and our additional results lead us to pre-
sent differing conclusions. In this work,we are able to confirm that
EBOVVP35 possesses two unique and independent binding sites
for NP interaction. We advance this finding to show that VP35
plays a similar role across the filoviruses in chaperoning NP as
an RNA-free monomer. Our thermodynamic analysis of the NP-
VP35 binding event suggests that a large conformational change
occurs upon binding, supporting the hypothesis that the VP35
N-terminal peptide is disordered in solution. The H/DXMS data
and extensive truncation studies presented here clearly delineate
the NP core domain and identify boundaries for the terminal olig-
omerization arms. Our smaller NP core (NP 34–367) is sufficient
for the VP35 N-terminal peptide interaction and interacts with
higher affinity (1 nM) than that observed by Leung et al. (2015)
(18–29 nM). This likely owes to the inclusion in the Leung et al.
(2015) construct (NP 25-457) of a portion of the N-terminal arm
domain. Our data suggest the N-terminal arm domain (NP 20–
29) competes with VP35 N-terminal peptide binding to the NP
core, and this competitionmay decrease the previously observed
affinity from that observed here. Similarly, Leung et al. (2015)
observe theNPaffinity forRNA tobe620nM,whereasweobserve
a much higher affinity of 20 nM. Again, this difference likely arises
from the different NP constructs used for these determinations.
Leung et al. (2015) use NP 25–457 for their RNA binding assays,
whereas here we use NP 1–450, the previously recognized region
sufficient for NP RNA binding and oligomerization (Noda et al.,
2011; Watanabe et al., 2006). Our data show that the N-terminal
arm isessential forNPoligomerizationand thatNPoligomerization
is important for RNA binding. The partial deletion of the N-terminal
arm inNP25–457 is likely todestabilize theoligomericNP.Accord-
ing to our model, in which a conformational change upon NP
oligomerization forms the RNA-binding site, deletion of half the
N-terminal oligomerization arm could destabilize the NP oligomer
and impair the affinity of NP for RNA. These affinity differences
highlight the importance of experimental identification of the
domain boundaries of the foldedNPcore (NP 34–367) and the ter-
minal arm domains (NP 20–29 and 357–381) prior to consideringmodels for VP35 and RNA binding to NP. While Leung et al.
(2015) and the data presented here both show that NP can be
dissociated into monomers by the VP35 peptide, we find that
this dissociation can only be accomplished when the NP 1–450
is purified free from RNA. The RNA content of the Leung et al.
(2015)NP1–457 sample is unclear. However, thepreviousconclu-
sion that the VP35 peptide dissociates NP-RNA oligomers is
inconsistent with the observations that oligomeric NP-RNA com-
plexes, whether in virions (Bharat et al., 2012), in cells (Noda
et al., 2011), or in vitro (as presented here), are not dissociated
into monomers when bound by VP35.
The structure by Leung et al. (2015) differs from the structures
presented here in the inclusion of a greater extent of the NP
C-terminal region. This NP C-terminal region forms an additional
helix whichmediates crystal contacts andmay represent a phys-
iological oliogomerization interaction between NP C-terminal
domains. These C-terminal helix interactions are not unique to
EBOV, but were also observed to occur in the oligomeric,
RNA-bound PIV5 nucleoprotein (Alayyoubi et al., 2015). Leung
et al.’s (2015) proposed function of this region is in agreement
with our H/DXMS data and accompanying NP truncation anal-
ysis using MALS and electron microscopy as well as our pro-
posed model for NP oligomerization.
Finally, Leung et al. (2015) propose a process of NP assembly
in which the VP35 N-terminal peptide is first removed from the
NP and then NP binds the RNA and finally NP oligomerizes.
The results presented here revise this model. We show that the
monomeric NP core has high affinity for the VP35 N-terminal
peptide and no appreciable affinity for RNA. Further, our
data show that NP oligomerization can occur independently of
RNA binding. Based on these results, we instead propose the
displacement of the VP35 peptide from NP by an incoming
NPi1 with subsequent RNA binding by the oligomeric NP.
In this work, we have shown that the ebolavirus VP35 contains
a chaperoning activity in its N-terminal region. This VP35 peptide
is responsible for preventing premature NP oligomerization and
RNA binding by maintaining the protein in a NP-VP35 complex.
This work has also yielded a higher resolution view of the chaper-
oned filovirus NP core domain structure and delineated the
regions of NP that likely correspond to the oligomerization-facil-
itating arm domains observed in other NNS virus nucleoproteins
(Ruigrok et al., 2011). The scope of data presented here has
granted a working model of NP assembly and RNA binding.
Given the high level of sequence conservation across the
filoviruses of both the VP35 N-terminal peptide and the NP
RNA-binding domain, these results and conclusions are likely
to be applicable across this family of viruses. Indeed, our data
show the VP35 chaperoning activity to follow suit for both
SUDV and MARV. These studies provide mechanistic insight
into the workings of the complex RNA replication machinery
belonging to this pathogenic family of viruses and yield a starting
point for targeting these weaknesses with antiviral drugs.EXPERIMENTAL PROCEDURES
Pulldowns
293T cells were transfected with HA-tagged full-length VP35 or VP35 trunca-
tion mutants in the vector pDisplay with an equal amount of NP-pcDNA. CellsCell Reports 12, 140–149, July 7, 2015 ª2015 The Authors 147
were lysed after 2 days, and HA-tagged VP35 was bound to anti-HA agarose
beads (Roche) and washed with lysis buffer. Beads were resuspended and
boiled in SDS-PAGE sample buffer prior to loading SDS-PAGE gels for western
blotting with anti-HA (VP35) or anti-NP antibodies.
Recombinant Protein Expression and Purification
Proteins were expressed in Escherichia coli using the pET46 vector (Novagen).
For VP35 + NP co-expressions, VP35 was cloned in frame with upstream His-
tags, and the two proteins were expressed from a bicistronic mRNA. For prepa-
rationofoligomericNP,anN-terminalMBP fusionwasusedasaspacerbetween
theHis-tagand theNP. Inall cases,Rosetta2pLysSE.coli (Novagen)were trans-
formedwith the expression vectors and inducedwith isopropylb-D-1-thiogalac-
topyranoside (IPTG) at an optical density at 600 nm of 0.4. Following overnight
expression at 25C, bacterial cultures were harvested and lysed using a micro-
fluidizer. Cleared lysates were applied to Ni-NTA Agarose and eluted with lysis
buffer containing 300-mM imidazole. For removal of purification tags, proteins
were incubated with 0.5% (w/w) TEV protease overnight at 4C. In cases where
the protein was subsequently purified by anion exchange (MonoQ), the proteins
were dialyzed beforehand into a low-salt buffer. All proteins were finally purified
by size exclusion chromatography (Superdex200). Nucleic acid content was as-
sessedbymeasuring theA260/A280 ratios of the purifiedproteins. A260/A280 ratios
less than 0.7 were considered to be RNA free.
Hydrogen/Deuterium Exchange Mass Spectrometry
The monomeric, chaperoned, fusion protein, VP35 1–80-NP 1–450 or in vitro
oligomerized, RNA-free NP 1–450 was diluted into D2O buffer for 10, 100, or
1,000 s. Reactions were quenched by the addition of guanidine hydrochloride,
glycerol, and formic acid. Proteins were digested with pepsin and subjected to
mass spectroscopic analysis.
Crystallization and Structure Solution
The EBOV VP35 15–60-NP 34–367 fusion protein was crystallized using sitting
drop vapor diffusion techniques at 4C.Crystalswere cryoprotected in glycerol
prior to cryo-cooling in liquid nitrogen. Data were collected at the Advanced
Photon Source at Argonne National Labs, beamlines 23ID-B and 23ID-D.
Data were reduced with XDS (Kabsch, 2010) and merged with AIMLESS
(Evans, 2011) or XSCALE (Kabsch, 2010). Structure solution was performed
in Phenix (Adams et al., 2010). Solutions were rebuilt in Coot (Emsley et al.,
2010) and refined with Phenix (Adams et al., 2010) and BUSTER-TNT (Blanc
et al., 2004) with final rounds of refinement in Refmac (Murshudov et al., 2011).
Multiangle Light Scattering
Approximately 100 mg of purified NP protein was used for light scattering ex-
periments. In cases where VP35 1–80 peptide was mixed with NP, a 50-fold
molar excess of peptide was used and the samples were incubated overnight
at 4C. Light scattering data were collected on a DawnMiniTreos (Wyatt Tech-
nologies) in line with a Superdex200 column and analyzed with ASTRA (Wyatt
Technologies).
Negative Stain Electron Microscopy
Copper grids (carbon coated, 400 mesh, Electron Microscopy Sciences) were
glow discharged. Samples were applied to grids and then stained with uranyl
acetate. Dried grids were examined on a Philips CM100 electron microscope
(FEI) at 80 kv.
ITC
Concentrated proteins were dialyzed overnight into matching buffers. NP
samples were loaded into the ITC cell, and VP35 peptide samples were loaded
into the syringe. Reactions were run by performing 20 injections of VP35 into
the cell at indicated temperatures. Data were processed using Origin
(OriginLab).
RNA-Binding Assay
Two-fold serial dilutions of EBOV NP proteins were mixed with carboxyfluoro-
scein-labeled 18 nucleotide RNA (final concentration 4 nM, Integrated DNA
Technologies). Fluorescence anisotropy was read on a Tecan Infinite 200
Pro (Rossi and Taylor, 2011).148 Cell Reports 12, 140–149, July 7, 2015 ª2015 The AuthorsMini-genome Assay
Screening of VP35 mutants was done as in (Jasenosky et al., 2010). HEK293T
cells were transfected with plasmids expressing NP, VP35, VP30, L, T7 RNA
polymerase, Renilla luciferase proteins, and the gene for firefly luciferase
flanked by viral sequences whose expression is driven by a T7 RNA polymer-
ase promoter. VP35 was either WT or mutated in the N-terminal conserved
region. Dual luciferase assays were performed according tomanufacturer’s in-
structions (Promega).
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